The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).

Igor Puzanov

Consultant or Advisory Role - GlaxoSmithKline

Margaret K. Callahan

Consultant or Advisory Role - GlaxoSmithKline

Research Funding - GlaxoSmithKline

Gerald P Linette

No relevant relationships to disclose

Sapna Pradyuman Patel

Research Funding - GlaxoSmithKline

Jason J. Luke

No relevant relationships to disclose

Jeffrey Alan Sosman

Consultant or Advisory Role - GlaxoSmithKline

Honoraria - GlaxoSmithKline

Research Funding - GlaxoSmithKline

Jedd D. Wolchok

Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck

Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck

Omid Hamid

Research Funding - GlaxoSmithKline

David R. Minor

Consultant or Advisory Role - GlaxoSmithKline

Honoraria - GlaxoSmithKline

Keith W. Orford